Viridian Therapeutics is a clinical-stage biotechnology company based in Waltham, Massachusetts, in the United States. It develops antibody-based medicines for serious autoimmune and inflammatory conditions, with its main work focused on treatments for thyroid eye disease. Its pipeline includes therapies designed to block a receptor involved in the disease process, and the company works with researchers and clinicians to test these candidates in clinical studies. Viridian's activities centre on drug development rather than on selling commercial products.
The shares are listed on the London Exchange in UK under the code 0K1R, and the price on this page is in US dollars (USD). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Market X-Ray · price-based
Weak price profile
Ranks #2706 of 3787 on the London Exchange · confidence High
What this score is, and is not
It describes how this stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is. That fundamental X-Ray needs financial statements, which we do not have for UK yet.
TrendWeak
41/100
Below its long-term averages and far from its highs.
See the numbers →
Above 200-day average2.2%
From 52-week high-34.4%
MomentumStrong
73/100
Rising faster than most stocks on this exchange.
See the numbers →
3-month return15.2%
6-month return58.3%
12-month, skipping last month-3.6%
Stability (higher is calmer)Weak
12/100
Volatile, with deep drawdowns.
See the numbers →
Volatility, 1 year (lower is calmer)75.3%
Worst drawdown, 1 year (smaller is calmer)-61.1%
LiquidityWeak
21/100
Thinly traded: prices can jump and exits can be hard.
See the numbers →
Avg daily value traded0.03M USD
Zero-volume days0.0%
IncomeNone
–/100
Pays no dividend.
See the numbers →
Years with dividends0
Price-based X-Ray. The fundamental X-Ray (financial health, valuation, growth, fair value) is available for US stocks today. It will follow for UK when fundamentals data for this market is added. All UK stocks.
52-wk range 13.25 – 34.31Daily closes, split-adjusted
Signals
50-day average21.59
200-day average21.89
Golden/death cross (60d)None
New 52-week highNo
Bullish RSI divergenceNo
Average daily range (ATR)1.00
Technical summary
Daily
Strongly bullish
12 bullish · 1 neutral · 3 bearish
Weekly
Strongly bullish
9 bullish · 1 neutral · 2 bearish
Monthly
Strongly bullish
6 bullish · 1 neutral · 1 bearish
Moving averages (daily)
SMA 10
20.48
Bullish
EMA 10
21.11
Bullish
SMA 20
19.85
Bullish
EMA 20
20.64
Bullish
SMA 50
21.59
Bullish
EMA 50
20.74
Bullish
SMA 100
20.23
Bullish
EMA 100
20.76
Bullish
SMA 200
21.89
Bullish
EMA 200
21.14
Bullish
Oscillators (daily)
RSI (14)
61.27
Neutral
MACD (12, 26)
0.27
Bullish
Momentum (12)
20.45
Bullish
Stochastic %K (14)
80.93
Bearish
Williams %R (14)
-19.07
Bearish
CCI (20)
139.1
Bearish
Pivot points (classic, last session)
S3
21.11
S2
21.54
S1
21.96
Pivot
22.39
R1
22.81
R2
23.24
R3
23.66
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.
Prices are end-of-day closes in USD. Educational only, not financial advice.
